{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:42:01Z","timestamp":1794811321813,"version":"4.9.1"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Elinzanetant is a dual neurokinin\u20131 and \u20133 receptor antagonist in development for treating vasomotor symptoms associated with menopause. Its central nervous system action and bedtime dosing could produce next\u2010morning residual effects that impact safety when driving. We therefore conducted a randomized, double\u2010blind, placebo\u2010 and active\u2010controlled, four\u2010period, crossover study to assess the effect of elinzanetant on next\u2010morning simulated driving performance. Sixty\u2010four healthy women aged 40\u201365\u2009years with regular sleep patterns were randomized to receive elinzanetant 120\u2009mg, elinzanetant 240\u2009mg, zopiclone 7.5\u2009mg, or placebo for 5\u2009days in one of four sequences. The primary endpoint assessed participant's ability to maintain a consistent position within the lane, measured using standard deviation of lateral position (SDLP). Secondary assessments included lane exceedance, cornering speeds, and treatment\u2010emergent adverse events (TEAEs), among others. The least squares mean SDLP for both doses of elinzanetant on Day 2 and Day 6 were significantly below the non\u2010inferiority margin of 4.4\u2009cm (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Small increases in SDLP with both doses versus placebo were observed on Day 2 but not on Day 6. Secondary assessments were not significantly different to placebo, apart from lane exceedances and cornering speed threshold exceedances. TEAEs were reported in 84% of participants; most were mild, and there was no increase in TEAE frequency with the 240\u2009mg dose. Our study demonstrated no clinically relevant next\u2010morning residual effects following bedtime elinzanetant dosing and confirmed the elinzanetant benefit: risk balance was not adversely impacted by somnolence or fatigue the following morning.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06219902\">ClinicalTrials.gov<\/jats:ext-link>\n                    identifier: NCT06219902\n                  <\/jats:p>","DOI":"10.1111\/cts.70282","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T10:19:19Z","timestamp":1750933159000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Effects of Elinzanetant on Simulated Driving Performance in Healthy Women: A Randomized Phase I Study"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4298-8057","authenticated-orcid":false,"given":"Klaus","family":"Francke","sequence":"first","affiliation":[{"name":"Bayer AG  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[{"name":"Bayer AG  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Burke","sequence":"additional","affiliation":[{"name":"Bayer US LLC  Whippany New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-6339","authenticated-orcid":false,"given":"Marcus\u2010Hillert","family":"Schultze\u2010Mosgau","sequence":"additional","affiliation":[{"name":"Bayer AG  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Kay","sequence":"additional","affiliation":[{"name":"Cognitive Research Corporation  St. Petersburg Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12004"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113517953"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.14618"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002471"},{"key":"e_1_2_10_6_1","unstructured":"US Department of Health and Human Services \u201cEvaluating Drug Effects on the Ability to Operate a Motor Vehicle \u201d Guidance for Industry (2017) https:\/\/www.fda.gov\/media\/90670\/download."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318\u2010024\u201000930\u20103"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13226"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615579314"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2484-0"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2592"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5168"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2530"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2603"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","unstructured":"G.Kay O.Ahmad T.Brown andA.Veit \u201cComparison of the MiniSim and STISIM Driving Simulators for the Detection of Impairment: An Alcohol Validation Study \u201d Seventh International Driving Symposium on Human Factors in Driver Assessment Training and Vehicle Design (2013) Bolton Landing NY USA.","DOI":"10.17077\/drivingassessment.1487"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2732"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-4575(02)00134-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12365"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199303050-00006"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13430"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.11.005"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.5665\/SLEEP.1272"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002138"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:46:17Z","timestamp":1774266377000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/cts.70282"],"URL":"https:\/\/doi.org\/10.1111\/cts.70282","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"2025-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70282"}}